Pioneering neuromodulation therapy for chronic migraine
Salvia BioElectronics is pioneering neuromodulation therapy aiming to transform the migraine treatment landscape. Designed to provide meaningful relief, MySalvia Therapy features an ultra-thin implant that comprehensively targets key nerves involved in migraine.
Salvia is driven by the belief that people with chronic migraine deserve the opportunity to reclaim their lives. Founded in 2017 and headquartered in Eindhoven, The Netherlands, Salvia is led by a team of industry veterans with extensive experience in medical devices and neuromodulation. Active in the United States, Europe and Australia, the company is advancing clinical development with the support of leading investors. Salvia is also exploring the potential of its technology for the treatment of cluster headache.
Salvia’s migraine therapy is currently being evaluated in clinical studies. It has not yet been approved for commercial use. No claims are made regarding its safety or effectiveness.
Meet our team
Salvia BioElectronics has experienced remarkable growth over the past seven years. We now have 50+ colleagues from all over the world, representing 17 nationalities. Our home is High Tech Campus Eindhoven, also known as the smartest square kilometer in Europe, where more than 300 high-tech companies are developing the technologies of the future.
Our team
Salvia BioElectronics secures $60M in oversubscribed Series B to bring its pioneering migraine therapy to market
Salvia BioElectronics, a clinical-stage medical device company pioneering neuromodulation therapy for people with chronic migraine, announced the successful completion of a $60 million (€53 million) Series B financing round. The round was led by Innovation Industries, a European deeptech venture capital firm, with participation from Invest-NL and EIC Fund. Existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, BOM and Thuja Capital also joined the round. The funds enable Salvia to complete clinical development and prepare for the commercial launch of MySalvia Therapy, which is currently evaluated in the RECLAIM study, a multi-center, double-blind, sham-controlled study for people with chronic migraine. The funds also allow Salvia to focus on obtaining FDA market authorization in the US and regulatory approvals in Europe and Australia.
It is not “just a headache”
Migraine affects more than one billion people worldwide each year and is the leading cause of disability in people under 50. Cluster headache, which causes excruciating pain behind the eye, is a rare neurological disorder affecting 1 in 1000 people. Read more about both conditions we address with our bioelectronic solution.
Join our team
Our team is growing and we are always looking for passionate and talented individuals who want to be part of our mission to give people with migraine a better life.
We also encourage open applications; please submit yours here!
Acquisition is not appreciated.
Manufacturing Engineer
You are responsible for the design, procurement, and realization of Salvia’s production and verification equipment. You will execute, supported by process engineering, required validations in line with regulatory requirements, including Equipment, Process & Product validations (IQ/OQ/PQ) and will drive process reliability and yield optimization from initial pilot production towards commercial scaling.
Senior Electronics Engineer
We offer a challenging position for an electronics engineer. Working closely together with our multidisciplinary team and with our suppliers, your responsibilities range from life cycle management up to bringing our product design to the next level through improvements for manufacturability and reliability. You realize that quality is of paramount importance, and you are passionate about delivering solutions that truly stand out.
Stay informed
Salvia BioElectronics strengthens Board of Directors with industry leader Rob ten Hoedt
“Joining Salvia’s Board of Directors is a great opportunity to support the advancement of a pioneering medtech approach with the potential to address a significant unmet medical need,” said Rob ten Hoedt, Member of Salvia’s Board of Directors.
Salvia BioElectronics secures $60M in oversubscribed Series B to bring its pioneering migraine therapy to market
Salvia BioElectronics, a clinical-stage medical device company pioneering neuromodulation therapy for people with chronic migraine, today announced the successful completion of a $60 million (€53 million) Series B financing round.
.jpg)
Founders with a mission: the story behind Salvia BioElectronics
Get to know the people behind Salvia, and the journey that brought them here.
Meet our investors
Salvia Insights
Later in 2025, we will provide updates on our latest clinical trials and other developments. Stay informed about Salvia's mission?
We value your privacy and will only use your email to send you updates about Salvia BioElectronics. Your information will always remain confidential and will not be shared with third parties. You can unsubscribe at any time.